Anúncio
Anúncio
CGON
CG Oncology, Inc. Common stock
41.78
USDPatrocinado
+0.26
+0.64%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
41.78
0.00
0.00%
Relatórios de Lucros CGON
Rácio de surpresa positiva
CGON separação 3 de 8 últimas estimativas.
38%
Próximo Relatório
Data do Próximo Relatório
26 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$484.50K
/-$0.62
Mudanças implicadas de Q3 25 (Revenue/ EPS)
-70.92%
/+10.71%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+6.25%
/+29.17%
CG Oncology, Inc. Common stock earnings per share and revenue
On 14 de nov. de 2025, CGON reported earnings of -0.56 USD per share (EPS) for Q3 25, beating the estimate of -0.57 USD, resulting in a 0.21% surprise. Revenue reached 1.67 milhão, compared to an expected 66.61 mil, with a 2401.28% difference. The market reacted with a +8.61% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 analistas forecast an EPS of -0.62 USD, with revenue projected to reach 484.50 mil USD, implying an aumentar of 10.71% EPS, and diminuir of -70.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were CG Oncology, Inc. Common stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, CG Oncology, Inc. Common stock reported EPS of -$0.56, missing estimates by 0.21%, and revenue of $1.67M, 2401.28% above expectations.
How did the market react to CG Oncology, Inc. Common stock's Q3 2025 earnings?
The stock price moved up 8.61%, changed from $37.76 before the earnings release to $41.01 the day after.
When is CG Oncology, Inc. Common stock expected to report next?
The next earning report is scheduled for 26 de mar. de 2026.
What are the forecasts for CG Oncology, Inc. Common stock's next earnings report?
Based on 17
analistas, CG Oncology, Inc. Common stock is expected to report EPS of -$0.62 and revenue of $484.50K for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio